Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT00002326
- Locations
- 🇺🇸
Natl Cancer Institute, Bethesda, Maryland, United States
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoechst Marion Roussel
- Target Recruit Count
- 144
- Registration Number
- NCT00002357
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Stanford Univ School of Medicine, Stanford, California, United States
🇺🇸Med College of Georgia, Augusta, Georgia, United States
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Target Recruit Count
- 160
- Registration Number
- NCT00002401
- Locations
- 🇺🇸
Pharmacia & Upjohn, Peapack, New Jersey, United States
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002048
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Regional Med Ctr at Memphis, Memphis, Tennessee, United States
🇺🇸Univ of South Florida, Tampa, Florida, United States
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00002386
- Locations
- 🇺🇸
Riley Hosp for Children, Indianapolis, Indiana, United States
🇺🇸Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002263
- Locations
- 🇺🇸
Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002286
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Registration Number
- NCT00002322
- Locations
- 🇺🇸
Infectious Disease Research Institute Inc, Tampa, Florida, United States
🇺🇸Boston City Hosp / FGH-1, Boston, Massachusetts, United States
🇺🇸East Orange Veterans Administration Med Ctr, East Orange, New Jersey, United States
A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Registration Number
- NCT00002435
- Locations
- 🇺🇸
Chelsea Village Med Ctr, New York, New York, United States
🇺🇸Goodgame Med Group, Maitland, Florida, United States
🇺🇸Infectious Disease Physicians Inc, Annandale, Virginia, United States
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT00002324
- Locations
- 🇺🇸
UCSD Treatment Ctr, San Diego, California, United States
🇺🇸Saint Francis Mem Hosp, San Francisco, California, United States
🇺🇸Univ of Utah School of Medicine, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.